Bactiguard Sets Audiocast for First-Quarter 2026 Results

An update from Bactiguard Holding AB ( ($SE:BACTI.B) ) is now available.

Bactiguard Holding AB, the Stockholm-headquartered infection-prevention MedTech company, will publish its interim report for the first quarter of 2026 on 23 April at 07:00 CET. The group’s technology, based on an ultra-thin noble metal coating for medical devices, targets infection-prone fields such as orthopedics, cardiology, neurology, urology, and vascular access, and is commercialized through global license partners and wound management products.

In conjunction with the Q1 report, Bactiguard will hold an audiocast for investors, analysts, and media at 11:00 CET the same day, where CEO Christine Lind and CFO Patrick Bach will present the results and take questions. The planned presentation underscores the company’s ongoing engagement with the capital market and other stakeholders at a time when infection prevention and antimicrobial resistance remain central issues for healthcare systems and MedTech investors alike.

More about Bactiguard Holding AB

Bactiguard is a global MedTech company that develops biocompatible infection-prevention technologies for medical devices. Its proprietary ultra-thin noble metal coating is designed to prevent bacterial adhesion and biofilm formation, supporting safer care in high-need therapeutic areas such as orthopedics, cardiology, neurology, urology, and vascular access.

The company commercializes its technology primarily through licensing partnerships with major international medical device manufacturers and also markets its own wound management products. Headquartered in Stockholm and listed on Nasdaq Stockholm’s Small Cap segment, Bactiguard positions its solutions as a way to reduce patient suffering, cut healthcare burdens, and combat antimicrobial resistance globally.

Average Trading Volume: 9,884

Technical Sentiment Signal: Sell

Current Market Cap: SEK588.7M

See more data about BACTI.B stock on TipRanks’ Stock Analysis page.